Blue Earth Diagnostics shortlisted for "Best Emerging Medtech Company" award
Oxford, UK - August 11, 2017 - Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced that it has been shortlisted as a finalist in the 2017 OBNawards in the category "Best Emerging Medtech Company". These prestigious awards, which are judged by a panel of leading industry entrepreneurs and experts, celebrate innovation and outstanding achievement across the UK's Life Sciences industry. The OBN's "Best Emerging Medtech Company" award goes to a company which is between two and five years old, which has raised significant growth capital and which is developing innovative, disruptive and novel products. The winner will show evidence of commercial planning and progress.
Blue Earth Diagnostics, which was formed in 2014, is focused on the development and commercialization of novel positron emission tomography (PET) imaging agents to inform clinical management and guide care for patients with cancer. The company, which has its headquarters in Oxford, UK, and a US office in Burlington, MA, is led by a team of recognized experts in the clinical development and commercialization of innovative nuclear medicine products. Blue Earth Diagnostics' PET imaging product Axumin™ (fluciclovine (18F)) is indicated in Europe for use in PET imaging to detect recurrence of prostate cancer in adult men with a suspected recurrence based on elevated blood prostate specific antigen (PSA) levels after primary curative treatment*. While most primary prostate cancer can be successfully treated, the disease recurs in up to one-third of patients. In some patients, recurrent disease is detectable only by a rise in PSA levels, but often the location of the recurrence cannot consistently be located by conventional imaging, limiting treatment guidance. Axumin was developed to target the increased amino acid transport that occurs in many cancers, including prostate cancer. It is labelled with the radioisotope (18F), enabling it to be visualized in the body with PET imaging.
Axumin is the first and only PET imaging agent approved by the European Commission for use in men with suspected recurrent prostate cancer in all European Union member states as well as in Iceland, Liechtenstein and Norway. Following receipt of marketing authorization for Axumin from the European Commission on May 22, 2017, Blue Earth Diagnostics is building a network of authorized and approved manufacturing locations across Europe.
Dr. Jonathan Allis, the founding CEO of Blue Earth Diagnostics commented, "We're delighted to receive the industry-wide recognition that being shortlisted for this prestigious award brings. We're on a mission to help improve the lives of people with cancer by developing and bringing to market innovative imaging agents that both inform and guide patient care. Receiving this nomination is both an honour for our whole team and a great endorsement of Blue Earth's progress over the last three years."
Dr John Harris, CEO of OBN (UK) said, "We received a high number of entries in the Best Emerging Medtech category and the standard of entries was consistently high. Blue Earth Diagnostics and all of the finalists are proof of the excellent innovation we are seeing in the medtech industry at this time, and we look forward to celebrating with all our finalists on 5th October at the Oxford Town Hall."
About Blue Earth Diagnostics
Blue Earth Diagnostics is a molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The Company's first approved and commercially available product is Axumin™ (fluciclovine F 18), a novel molecular imaging agent approved in the United States and the European Union for use in PET imaging to detect and localize prostate cancer in men experiencing suspected biochemical recurrence. The Company is backed by Syncona Limited, a leading FTSE250 company listed on the London Stock Exchange (LON:SYNC) focused on investing in and building global leaders in life sciences. For more information, visit: